The FDA may soon join forces with personal genomics companies like 23andMe and CIMR in order to draw associations between genotypes and adverse drug reactions. ScienceBlogger Revere from Genetic Future posted that before such a collaborationis considered, genomics companies must recruit more—and more diverse—participants and improve methodology to gather "extremely accurate and detailed" clinical data about them and their drug regimens. "Any genome-wide association study is only as good as the clinical data it's based around," he wrote.
- Log in to post comments
More like this
Update 30/11/10: 23andMe has extended their 80% discount until Christmas, without a need for a discount code.
Personal genomics company 23andMe has made some fairly major announcements this week: a brand new chip, a new product strategy (including a monthly subscription fee), and yet another…
There are new articles in four PLoS journals today. As always, you should rate the articles, post notes and comments and send trackbacks when you blog about the papers. You can now also easily place articles on various social services (CiteULike, Mendeley, Connotea, Stumbleupon, Facebook and Digg…
Welcome to the new look Genetic Future, now hosted on ScienceBlogs.
In around five years, a complete genome sequence will be readily affordable for most citizens of wealthy industrialised nations - even those of us on a researcher's salary. At the same time we will have access to vast amounts of…
Logo by Ricardo at My Biotech Life
Welcome to the 33rd edition of Gene Genie, the blog carnival devoted to genes and genetic diseases.
In this edition, there is a strong emphasis on cancer. There's also a focus on leukodystrophy, and a special section on personalized genetics.
Spotlight on…